Fredag 27 December | 11:35:54 Europe / Stockholm
Svenska | English

Cinclus Pharma

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-05-22 N/A Årsstämma
2025-05-19 N/A Kvartalsrapport 2025-Q1
2025-02-20 N/A Bokslutskommuniké 2024
2024-11-14 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriBioteknik
Cinclus Pharma är ett svenskt läkemedelsbolag i klinisk fas. Bolaget är verksamt inom utveckling av molekyler för behandling av syrarelaterade sjukdomar. Bolagets ledande läkemedelskandidat linaprazan glurate utvecklas för behandling av svår gastroesofageal refluxsjukdom (GERD). Cinclus Pharma grundades år 2014 och har sitt huvudkontor i Stockholm.
Number of shares and votes in Cinclus Pharma
2024-06-28 08:45:00

The number of shares and votes in Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) has changed as a result of the share issues carried out in connection with the listing of Cinclus Pharma’s ordinary shares on Nasdaq Stockholm on 20 June 2024.

Through the new share issues, the number of shares and votes has increased by 20,310,749, from 26,227,040 to 46,537,789 shares and votes. The share capital has increased by approximately SEK 394,298, from SEK 509,153 to approximately SEK 903,451.

This information is information that Cinclus Pharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-06-28 08:45 CEST.

For additional information, please contact:

Christer Ahlberg, CEO
Phone: +46 70 675 33 30
e-mail: christer.ahlberg@cincluspharma.com

Charlotte Stjerngren, IR
Phone: +46 70 876 87 87
e-mail: charlotte.stjerngren@cincluspharma.com

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a clinical stage pharma company developing a molecule for the treatment of gastric acid-related diseases and H. pylori infection. Its drug candidate linaprazan glurate represents a novel class of drugs, Potassium-Competitive Acid Blockers (P‑CAB), and provides a fast-acting control of intragastric pH by a different mechanism of action than proton pump inhibitors (PPIs). For more information, please visit www.cincluspharma.com.

Attachments

Number of shares and votes in Cinclus Pharma

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden